{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T02:09:47Z","timestamp":1777774187621,"version":"3.51.4"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020760","name":"Sanya Yazhou Bay Science and Technology City","doi-asserted-by":"publisher","award":["SKJC-2022-01-002"],"award-info":[{"award-number":["SKJC-2022-01-002"]}],"id":[{"id":"10.13039\/100020760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020760","name":"Sanya Yazhou Bay Science and Technology City","doi-asserted-by":"publisher","award":["SKJC-2024-03-001"],"award-info":[{"award-number":["SKJC-2024-03-001"]}],"id":[{"id":"10.13039\/100020760","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020760","name":"Sanya Yazhou Bay Science and Technology City","doi-asserted-by":"publisher","award":["DSTIC-CYCJ-2023012"],"award-info":[{"award-number":["DSTIC-CYCJ-2023012"]}],"id":[{"id":"10.13039\/100020760","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijbiomac.2026.150642","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T17:04:42Z","timestamp":1769792682000},"page":"150642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A shark VNAR-IL-15 fusion protein that suppresses TROP2+ tumor growth"],"prefix":"10.1016","volume":"346","author":[{"given":"Zhongqiu","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ling","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchao","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming-Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.ijbiomac.2026.150642_bb0005","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.ijbiomac.2026.150642_bb0010","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.150642_bb0015","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning cold into hot: firing up the tumor microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150642_bb0020","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2026.150642_bb0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1200\/EDBK_240837","article-title":"Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients?","volume":"39","author":"Fares","year":"2019","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150642_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188902","article-title":"Targeting Trop-2 in cancer: recent research progress and clinical application","volume":"1878","author":"Qiu","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.150642_bb0035","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/sj.bjc.6604677","article-title":"High expression of TROP2 correlates with poor prognosis in pancreatic cancer","volume":"99","author":"Fong","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.150642_bb0040","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/pin.12911","article-title":"Clinical impact of TROP2 in non-small lung cancers and its correlation with abnormal p53 nuclear accumulation","volume":"70","author":"Mito","year":"2020","journal-title":"Pathol. Int."},{"issue":"16","key":"10.1016\/j.ijbiomac.2026.150642_bb0045","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150642_bb0050","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1535-7163.MCT-21-0580","article-title":"Cellular-resolution imaging of bystander payload tissue penetration from antibody-drug conjugates","volume":"21","author":"Khera","year":"2022","journal-title":"Mol. Cancer Ther."},{"issue":"8","key":"10.1016\/j.ijbiomac.2026.150642_bb0055","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150642_bb0060","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2174\/157489210791760490","article-title":"Insights into the role of Fc gamma receptors (FcgammaRs) genetic variations in monoclonal antibody-based anti-cancer therapy","volume":"5","author":"Concetti","year":"2010","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"10.1016\/j.ijbiomac.2026.150642_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.123795","article-title":"Biodistribution and pharmacokinetics of [(89)Zr]-anti-VEGF mAbs using PET in glioblastoma rat models","volume":"652","author":"Garc\u00eda-Varela","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150642_bb0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4161\/19420862.2015.989032","article-title":"Structural insights and biomedical potential of IgNAR scaffolds from sharks","volume":"7","author":"Zielonka","year":"2015","journal-title":"MAbs"},{"issue":"51","key":"10.1016\/j.ijbiomac.2026.150642_bb0075","doi-asserted-by":"crossref","first-page":"37191","DOI":"10.1074\/jbc.M706150200","article-title":"Crystal structure of the interleukin-15.interleukin-15 receptor alpha complex: insights into trans and cis presentation","volume":"282","author":"Olsen","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"6518","key":"10.1016\/j.ijbiomac.2026.150642_bb0080","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/374168a0","article-title":"A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks","volume":"374","author":"Greenberg","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.ijbiomac.2026.150642_bb0085","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu. Rev. Biochem."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150642_bb0090","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12951-025-03150-2","article-title":"A shark-derived broadly neutralizing nanobody targeting a highly conserved epitope on the S2 domain of sarbecoviruses","volume":"23","author":"Feng","year":"2025","journal-title":"J. Nanobiotechnol."},{"issue":"5691","key":"10.1016\/j.ijbiomac.2026.150642_bb0095","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1126\/science.1101148","article-title":"Crystal structure of a shark single-domain antibody V region in complex with lysozyme","volume":"305","author":"Stanfield","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ijbiomac.2026.150642_bb0100","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.dci.2018.09.007","article-title":"Shark IgNAR-derived binding domains as potential diagnostic and therapeutic agents","volume":"90","author":"Matz","year":"2019","journal-title":"Dev. Comp. Immunol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2026.150642_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/md21090496","article-title":"Shark IgNAR: the next broad application antibody in clinical diagnoses and tumor therapies?","volume":"21","author":"Jiang","year":"2023","journal-title":"Mar. Drugs"},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150642_bb0110","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.molimm.2014.02.014","article-title":"Thermal stability and refolding capability of shark derived single domain antibodies","volume":"59","author":"Liu","year":"2014","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ijbiomac.2026.150642_bb0115","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.01780","article-title":"Novel, anti-hTNF-\u03b1 variable new antigen receptor formats with enhanced neutralizing potency and multifunctionality, generated for therapeutic development","volume":"8","author":"Ubah","year":"2017","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.150642_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051140","article-title":"Shark new antigen receptor (IgNAR): structure, characteristics and potential biomedical applications","volume":"10","author":"Juma","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ijbiomac.2026.150642_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bea.2022.100054","article-title":"Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses","volume":"4","author":"Lim","year":"2022","journal-title":"Biomed. Eng. Adv."},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.150642_bb0130","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1084\/jem.191.5.771","article-title":"Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice","volume":"191","author":"Kennedy","year":"2000","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijbiomac.2026.150642_bb0135","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.molimm.2019.11.011","article-title":"Control of memory CD8(+) T cell longevity and effector functions by IL-15","volume":"117","author":"Nolz","year":"2020","journal-title":"Mol. Immunol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150642_bb0140","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1006\/cimm.1995.1216","article-title":"Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2","volume":"165","author":"Munger","year":"1995","journal-title":"Cell. Immunol."},{"issue":"7395","key":"10.1016\/j.ijbiomac.2026.150642_bb0145","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature10975","article-title":"Exploiting a natural conformational switch to engineer an interleukin-2 \u2018superkine\u2019","volume":"484","author":"Levin","year":"2012","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ijbiomac.2026.150642_bb0150","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1007\/s00262-019-02354-4","article-title":"Comparison of IL-2 vs IL-7\/IL-15 for the generation of NY-ESO-1-specific T cells","volume":"68","author":"Gong","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150642_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000599","article-title":"Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-\u03b3, CXCL9 and CXCL10","volume":"8","author":"Bergamaschi","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"5","key":"10.1016\/j.ijbiomac.2026.150642_bb0160","article-title":"Next-generation anti-PD-L1\/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity","volume":"5","author":"Shi","year":"2024","journal-title":"Cell Rep. Med."},{"issue":"23","key":"10.1016\/j.ijbiomac.2026.150642_bb0165","doi-asserted-by":"crossref","first-page":"10619","DOI":"10.7150\/thno.44871","article-title":"CDK4\/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ijbiomac.2026.150642_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108677","article-title":"Development of a recombinant human IL-15\u00b7sIL-15R\u03b1\/Fc superagonist with improved half-life and its antitumor activity alone or in combination with PD-1 blockade in mouse model","volume":"112","author":"Zhao","year":"2019","journal-title":"Biomed. Pharmacother."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150642_bb0175","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12934-021-01605-3","article-title":"Development of IL-15\/IL-15R\u03b1 sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives","volume":"20","author":"Xu","year":"2021","journal-title":"Microb. Cell Factories"},{"key":"10.1016\/j.ijbiomac.2026.150642_bb0180","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cyto.2018.01.011","article-title":"Optimized administration of hetIL-15 expands lymphocytes and minimizes toxicity in rhesus macaques","volume":"108","author":"Bergamaschi","year":"2018","journal-title":"Cytokine"},{"issue":"18","key":"10.1016\/j.ijbiomac.2026.150642_bb0185","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1182\/blood-2010-10-311456","article-title":"Safety (toxicity), pharmacokinetics, immunogenicity, and impact on elements of the normal immune system of recombinant human IL-15 in rhesus macaques","volume":"117","author":"Waldmann","year":"2011","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150642_bb0190","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/nbt0302-264","article-title":"Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature","volume":"20","author":"Halin","year":"2002","journal-title":"Nat. Biotechnol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2026.150642_bb0195","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s002620050256","article-title":"Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2","volume":"42","author":"Pancook","year":"1996","journal-title":"Cancer Immunol. Immunother."},{"issue":"450","key":"10.1016\/j.ijbiomac.2026.150642_bb0200","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"17","key":"10.1016\/j.ijbiomac.2026.150642_bb0205","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1097\/QAD.0000000000000444","article-title":"Identification of antibody glycosylation structures that predict monoclonal antibody Fc-effector function","volume":"28","author":"Chung","year":"2014","journal-title":"Aids"},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.150642_bb0210","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1016\/j.apsb.2024.08.023","article-title":"A novel shark VNAR antibody-based immunotoxin targeting TROP-2 for cancer therapy","volume":"14","author":"Xi","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"3","key":"10.1016\/j.ijbiomac.2026.150642_bb0215","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.cyto.2011.09.028","article-title":"IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization","volume":"56","author":"Han","year":"2011","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.ijbiomac.2026.150642_bb0220","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.4049\/jimmunol.0901244","article-title":"Novel human interleukin-15 agonists","volume":"183","author":"Zhu","year":"2009","journal-title":"J. Immunol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.150642_bb0225","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1158\/0008-5472.CAN-12-2357","article-title":"Efficacy and mechanism-of-action of a novel superagonist interleukin-15: interleukin-15 receptor \u03b1Su\/Fc fusion complex in syngeneic murine models of multiple myeloma","volume":"73","author":"Xu","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.150642_bb0230","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.cytogfr.2017.08.002","article-title":"Immunobiology of the IL-15\/IL-15R\u03b1 complex as an antitumor and antiviral agent","volume":"38","author":"Guo","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"issue":"8016","key":"10.1016\/j.ijbiomac.2026.150642_bb0235","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150642_bb0240","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/s41467-024-44789-z","article-title":"Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity","volume":"15","author":"Dean","year":"2024","journal-title":"Nat. Commun."},{"issue":"43","key":"10.1016\/j.ijbiomac.2026.150642_bb0245","doi-asserted-by":"crossref","first-page":"43826","DOI":"10.1021\/acsomega.4c06761","article-title":"A PD-L1-targeted probe Cy5.5-A11 for in vivo imaging of multiple tumors","volume":"9","author":"Cao","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.ijbiomac.2026.150642_bb0250","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.coi.2016.03.006","article-title":"Immunocytokines for cancer treatment: past, present and future","volume":"40","author":"Neri","year":"2016","journal-title":"Curr. Opin. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150642_bb0255","first-page":"1","article-title":"Ancient species offers contemporary therapeutics: an update on shark V(NAR) single domain antibody sequences, phage libraries and potential clinical applications","volume":"3","author":"English","year":"2020","journal-title":"Antib. Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150642_bb0260","doi-asserted-by":"crossref","first-page":"2406539","DOI":"10.1080\/19420862.2024.2406539","article-title":"Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors","volume":"16","author":"Hale","year":"2024","journal-title":"MAbs"},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150642_bb0265","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","article-title":"Fc\u03b3 receptor-dependent internalization and off-target cytotoxicity of antibody-drug conjugate aggregates","volume":"39","author":"Aoyama","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijbiomac.2026.150642_bb0270","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1146\/annurev.immunol.24.021605.090727","article-title":"Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis","volume":"24","author":"Ma","year":"2006","journal-title":"Annu. Rev. Immunol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2026.150642_bb0275","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26442","article-title":"The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity","volume":"2","author":"Wong","year":"2013","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.ijbiomac.2026.150642_bb0280","first-page":"1671","article-title":"Shedding light on triple-negative breast cancer with Trop2-targeted antibody-drug conjugates","volume":"12","author":"Jabbarzadeh Kaboli","year":"2022","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.150642_bb0285","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.nbt.2019.04.002","article-title":"Antibody-cytokine fusion proteins: a novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation","volume":"52","author":"Murer","year":"2019","journal-title":"New Biotechnol."},{"issue":"44","key":"10.1016\/j.ijbiomac.2026.150642_bb0290","doi-asserted-by":"crossref","first-page":"3972","DOI":"10.18632\/oncotarget.27772","article-title":"Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors","volume":"11","author":"Mortensen","year":"2020","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.ijbiomac.2026.150642_bb0295","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220745","article-title":"An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery","volume":"219","author":"Shen","year":"2022","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150642_bb0300","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.150642_bb0305","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/s41590-024-01925-7","article-title":"Local delivery of cell surface-targeted immunocytokines programs systemic antitumor immunity","volume":"25","author":"Santollani","year":"2024","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2026.150642_bb0310","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12987-020-00230-3","article-title":"A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity","volume":"17","author":"Kadry","year":"2020","journal-title":"Fluids Barriers CNS"},{"key":"10.1016\/j.ijbiomac.2026.150642_bb0315","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cbpa.2021.01.009","article-title":"Not so innocent: impact of fluorophore chemistry on the in vivo properties of bioconjugates","volume":"63","author":"Usama","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2026.150642_bb0320","doi-asserted-by":"crossref","first-page":"13272","DOI":"10.1096\/fj.202000610RR","article-title":"Brain delivery of biologics using a cross-species reactive transferrin receptor 1 VNAR shuttle","volume":"34","author":"Sehlin","year":"2020","journal-title":"FASEB J."},{"key":"10.1016\/j.ijbiomac.2026.150642_bb0325","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.2147\/DDDT.S166373","article-title":"A novel multifunctional anti-CEA-IL-15 molecule displays potent antitumor activities","volume":"12","author":"Liu","year":"2018","journal-title":"Drug Des. Devel. Ther."}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026005684?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026005684?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T17:38:56Z","timestamp":1777484336000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026005684"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":65,"alternative-id":["S0141813026005684"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150642","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A shark VNAR-IL-15 fusion protein that suppresses TROP2+ tumor growth","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150642","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"150642"}}